EasySep™小鼠TIL（CD45）正选试剂盒
搜索结果: 'methocult media formulations for human hematopoietic cells serum containing'
-
STEMCELL Technologies Inc. to Host Stem Cell Training Courses STEMCELL Technologies has announced the schedule for their fall training program -
STEMCELL Technologies to Commercialize BrainPhys™ Neuronal Culture Medium for Improved Support of Neurophysiological Activity STEMCELL Technologies has announced that it has signed a license agreement with the Salk Institute for Biological Studies for the rights to commercialize BrainPhys™ Neuronal Medium -
STEMCELL Technologies is Proud to Announce STEMcircles™, a Virus-Free Technology for Reprogramming Cells STEMCELL Technologies Inc announced today that they have signed a licensing agreement with Stanford University for a virus-free technique used for the generation of induced pluripotent stem cells -
STEMCELL Technologies Signs Exclusive License to Commercialize Human Pluripotent Stem Cell-Derived Kidney Organoid Culture System STEMCELL Technologies has today announced that they have signed an exclusive license agreement with Brigham and Women's Hospital for rights to commercialize technologies for the generation of human pluripotent stem cell-derived kidney organoids -
STEMCELL Technologies Signs Exclusive License Agreement with Cincinnati Children’s for Stem Cell-Derived Organoid Technology This agreement grants STEMCELL a license to novel methods for generating organoid models and to develop cell culture media and tools that would enable scientists to create organoids from PSCs in their own laboratories -
STEMCELL Submits Drug Master File for mTeSR™1, the Most Widely Published Cell Culture Medium for Human Pluripotent Stem Cells STEMCELL Technologies announced it has filed a Type II Drug Master File (DMF) to the Food and Drug Administration (FDA) for the Cellular Therapy Ancillary Material mTeSR™1 and has been issued DMF# 18339 -
New Video: Untouched cells in one step with RosetteSep™ STEMCELL Technologies is proud to present an exciting new video showcasing RosetteSep™, a one-step cell separation procedure by negative selection -
GE Healthcare expands cell therapy portfolio with license of STEMCELL Technologies’ T-Cell reagents Exclusive licensing agreement will provide cGMP grade reagents to further enable development and manufacturing of cellular immunotherapies
